PFE logo

Pfizer Inc. Stock Price

NYSE:PFE Community·US$150.3b Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 891 Fair Values set on narratives written by author

PFE Share Price Performance

US$26.27
-2.91 (-9.97%)
26.5% undervalued intrinsic discount
US$35.77
Fair Value
US$26.27
-2.91 (-9.97%)
30.7% undervalued intrinsic discount
US$37.92
Fair Value
Price US$26.27
AnalystHighTarget US$37.92
AnalystConsensusTarget US$28.77
AnalystLowTarget US$23.58

PFE Community Narratives

AnalystHighTarget·
Fair Value US$35.77 26.5% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Unlock New Opportunities

2users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
AnalystConsensusTarget·
Fair Value US$28.86 9.0% undervalued intrinsic discount

Expanding Oncology Pipelines And Emerging Markets Will Unlock Future Success

5users have liked this narrative
1users have commented on this narrative
444users have followed this narrative
AnalystLowTarget·
Fair Value US$24 9.5% overvalued intrinsic discount

Rising Regulatory Hurdles Will Undercut Pharmaceutical Profits Despite Pipeline Hope

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative

PFE Community Fair Values

Recent PFE News & Updates

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

Pfizer Inc. Key Details

US$63.8b

Revenue

US$16.7b

Cost of Revenue

US$47.1b

Gross Profit

US$36.4b

Other Expenses

US$10.7b

Earnings

Last Reported Earnings
Jun 29, 2025
Next Reporting Earnings
Nov 04, 2025
Earnings per share (EPS)
1.89
Gross Margin
73.82%
Net Profit Margin
16.81%
Debt/Equity Ratio
69.7%

Pfizer Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

6 star dividend payer and undervalued.

2 Risks
4 Rewards

About PFE

Founded
1849
Employees
81000
CEO
Albert Bourla
WebsiteView website
www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.4%
  • 3 Months: 7.8%
  • 1 Year: 17.8%
  • Year to Date: 14.7%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 3.7% in that time. Meanwhile, the market is actually up 18% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›